Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service

Paper. Harrison HV, Gaillard M, Cook RR et al.. Frontiers in Public Health, 16 Sep 2026.

Tags: Human, Observational, Psilocybin.

Weekly Science Digest, 26 Sep 2026 to 2 Oct 2026, finding 2: Safety evidence came from surveys and case notes

This week's safety data are observational, and one case report documents psilocybin making things worse.

JAMA Network Open published a nationally representative US cross-sectional survey of health outcomes attributed to recent psilocybin, LSD, MDMA, ibogaine and 5-MeO-DMT use. A separate case report describes worsening depression and anxiety after psilocybin in cyclothymia, and an Oregon risk-reduction consult service (n=29) found most patients low-risk, with 17% reporting a prior challenging experience.

Read the original

—
Node—
Statuslive
Throughput—